E!1705 - GEN209 - Breakthrough biological treatment for triple negative breast cancer (TNBC) Genagon Therapeutics AB
| Reference number | |
| Coordinator | Region Uppsala - Akademiska sjukhuset Kliniken för allmän onkologi |
| Funding from Vinnova | SEK 1 955 624 |
| Project duration | September 2022 - August 2025 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
The Swedish scale-up company Genagon Therapeutics, together with Mosaique Diagnostics, receive 7 MSEK in funding from Eurostar for the continued development of biological treatment for triple negative breast cancer. The consortium partners aim to jointly undertake major steps towards the transition from the preclinical to clinical development of GEN209 - a drug candidate for triple-negative breast cancer (TNBC). This will be a first-in-class monoclonal antibody-drug conjugate (ADC) targeting Clptm1, a novel molecular target expressed in solid tumors.
Expected effects and result
This will help us secure in vivo efficacy data, identify biomarkers for patient selection and treatment outcome follow-up. We will also design regulatory and toxicology programs allowing for a successful transition to clinical trials”, says Moa Fransson, CEO at Genagon Therapeutics.
Planned approach and implementation
The consortia will secure in vivo efficacy data, identify biomarkers for patient selection for the lead drug in a series of work packages divided between Genagon Therapeutics and Mosaique Diagnostics. Genagon will be the coordinating part for evaluating the and securing efficacy and safety data around the lead candidate and Mosaique Diagnostics will design a biomarker panel to be included as selection criteria and treatment follow-up in the clinical trial.